Skip to main content

Advertisement

SpringerLink
Log in

Positive impact of blocking tumor necrosis factor α on the nutritional status in pediatric Crohn’s disease patients

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

TNFα seems to contribute to inflammation and malnutrition in Crohn’s disease (CD) patients. In CD patients, the comparative effects on nutritional status of infliximab and traditional therapy have not yet been determined. The aim of our study was to assess the effects of infliximab as compared with those of standard therapy on nutritional status, disease activity, resting energy expenditure (REE), and food intake in CD children and adolescents.

Methods

From September 1999 to September 2005, all CD patients treated with infliximab (group A) were reviewed and matched with CD patients treated with traditional therapy (mesalazine and azathioprine) (group B).

Results

Fourteen CD patients from group A and 14 from group B were included; median interval before follow-up investigation was 10 months. Baseline and final values of weight, height, body mass index (BMI), pediatric CD activity index (pCDAI), REE, and food intake were studied. In treated patients, but not in control group, mean baseline weight (kg) and BMI values, 39.7 ± 13.1 and 17.9 ± 3.3, respectively, were significantly lower than their final values 42.6 ± 13.2 and 18.9 ± 3.1, and median pCDAI values 23.5 were significantly higher than their final values 10 (P < 0.05). Significant changes in height, REE, and food intake were not found in either group.

Conclusions

In pediatric CD patients, infliximab seems to impact positively on the nutritional status as demonstrated by the improvement in weight and BMI, but not in linear growth; effects on nutritional status seem to be due to amelioration of disease activity, rather than to REE reduction or food intake increase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cezard JP, Touati G, Alberti C et al (2002) Growth in pediatric Crohn’s disease. Horm Res 58:11–15

    Article  PubMed  CAS  Google Scholar 

  2. Savage MO, Beattie RM, Camacho-Hubner C et al (1999) Growth in Crohn’s disease. Acta Paediatrica 88:89–92

    Article  CAS  Google Scholar 

  3. Griffiths AM, Phoungbich N, Smith C et al (1993) Growth and clinical course of children with Crohn’s disease. Gut 34:939–943

    Article  PubMed  CAS  Google Scholar 

  4. Newby EA, Sawczenko A, Thomas AG, Wilson D (2005) Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev 20(3):CD003873

    Google Scholar 

  5. Walters TD, Gilman AR, Griffiths AM (2007) Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis 13(4):424–430

    Article  PubMed  Google Scholar 

  6. Söderholm JD, Streutker C, Yang PC et al (2004) Increased epithelial uptake of protein antigens in the ileum of Crohn’s disease mediated by tumor necrosis factor α. Gut 53:1817–1824

    Article  PubMed  CAS  Google Scholar 

  7. Gibson PR (2004) Increased gut permeability in Crohn’s disease: is TNF the link. Gut 53:1724–1725

    Article  PubMed  CAS  Google Scholar 

  8. Yan F, John SK, Wilson G et al (2004) Kinase suppressor of Ras-1 protects intestinal epithelium from cytokine-mediated apoptosis during inflammation. J Clin Invest 114(9):1272–1280

    PubMed  CAS  Google Scholar 

  9. Escher JC, Taminiau JAJM, Nieuwenhuis EES et al (2003) Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 9:34–58

    Article  PubMed  Google Scholar 

  10. Kleinman RE, Baldassano RN, Caplan A et al (2004) Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 39:15–27

    Article  PubMed  Google Scholar 

  11. Manolagas SC, Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305–311

    Article  PubMed  CAS  Google Scholar 

  12. Baldassano R, Braegger CP, Escher JC et al (2003) Infliximab therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 98:833–838

    Article  PubMed  CAS  Google Scholar 

  13. Borrelli O, Bascietto C, Viola F et al (2004) Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 36:342–347

    Article  PubMed  CAS  Google Scholar 

  14. Tynjala P, Lahdenne P, Vahasalo P et al (2006) Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 65:1044–1049

    Article  PubMed  CAS  Google Scholar 

  15. Hyams J, Crandall W, Kugathasan S et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132(3):863–873

    Article  PubMed  CAS  Google Scholar 

  16. Franchimont D, Roland S, Gustot T et al (2005) Impact of infliximab on serum leptin levels in patients with Crohn’s disease. J Clin Endocrinol Metab 90:3510–3516

    Article  PubMed  CAS  Google Scholar 

  17. NASPGHAN (2007) Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the NASPGHAN and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 44:653–674

    Article  Google Scholar 

  18. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (2005) Inflammatory bowel disease in children and adolescents: recommendations for diagnosis—the Porto criteria. J Pediatr Gastroenterol Nutr 41(1):1–7

    Article  Google Scholar 

  19. Hyams JS, Ferry GD, Mandel FS et al (1991) Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 12:439–447

    PubMed  CAS  Google Scholar 

  20. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT 1 randomised trial. Lancet 342:174–175

    Google Scholar 

  21. Levine A, Broide E, Stein M et al (2002) Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn’s disease. J Pediatr 140:75–80

    Article  PubMed  CAS  Google Scholar 

  22. Schofield W (1985) Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 39:5–41

    PubMed  Google Scholar 

  23. Food and Nutrition Board, National Research Council (1989) Recommended Dietary Allowances, 10th edn. National Academy Press, Washington, DC

    Google Scholar 

  24. Kundhal P, Zachos M, Holmes JL, Griffiths AM (2001) Controlled ileal release budesonide in pediatric Crohn’s disease: efficacy and effects on growth. J Pediatr Gatroenterol Nutr 33:75–80

    Article  CAS  Google Scholar 

  25. Markowitz J, Grancher K, Kohn N et al (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 119:895–902

    Article  PubMed  CAS  Google Scholar 

  26. Berni Canani R, Terrin G, Borrelli O et al (2006) Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis 38(6):381–387

    Article  PubMed  CAS  Google Scholar 

  27. Cezard JP, Nouaili N, Talbotec C et al (2003) A prospective study of the efficacy and tolerance of chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn’s disease. J Pediatr Gatroenterol Nutr 36:632–636

    Article  CAS  Google Scholar 

  28. deRidder L, Escher J, Bouquet J et al (2004) Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J Pediatr Gatroenterol Nutr 39:46–52

    Article  CAS  Google Scholar 

  29. Ballinger A (2002) Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm Res 58:7–10

    Article  PubMed  CAS  Google Scholar 

  30. Hart JW, Bremner AR, Wootton SA, Beattie RM (2005) Measured versus predicted energy expenditure in children with inactive Crohn’s disease. Clin Nutr 24:1047–1055

    Article  PubMed  CAS  Google Scholar 

  31. Azcue M, Rashid M, Griffiths A, Pencharz PB (1997) Energy expenditure and body composition in children with Crohn’s disease: effect of enteral nutrition and treatment with prednisolone. Gut 41:203–208

    Article  PubMed  CAS  Google Scholar 

  32. Varille V, Cezard JP, de Lagausie P, Bellaiche M et al (1996) Resting energy expenditure before and after gut resection of gut lesions in pediatric Crohn’s disease. J Pediatr Gatroenterol Nutr 9:13–9

    Article  Google Scholar 

  33. Kushner RF, Schoeller DA (1991) Resting energy expenditure in patients with inflammatory bowel disease. Am J Clin Nutr 53:161–165

    PubMed  CAS  Google Scholar 

  34. Andrassy RJ, Chwals WJ (1998) Nutritional support of the pediatric oncology patient. Nutrition 14:124–129

    Article  PubMed  CAS  Google Scholar 

  35. Cole TJ (2004) Children grow and horses race: is the adiposity rebound a critical period for later obesity. BMC Pediatrics 4:6–12

    Article  PubMed  CAS  Google Scholar 

  36. Segal KR, Burastero S, Chun A et al (1991) Estimation of extracellular and total body water by multiple-frequency bioelectrical-impedance measurement. Am J Clin Nutr 54:26–29

    PubMed  CAS  Google Scholar 

  37. Rosenbaum M, Leibel RL, Hirsch J (1997) Obesity. N Engl J Med 337:396–407

    Article  PubMed  CAS  Google Scholar 

  38. Gordon CM, Goodman E, Emans SJ et al (2002) Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr 141:64–70

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors would like to thank Mrs. Karen Christenfeld for her considerable help in writing the manuscript.

Author information

Authors and Affiliations

  1. Gastroenterology and Nutrition Unit, Bambino Gesù Children’s Hospital, Piazza S. Onofrio, 4-00165, Rome, Italy

    A. Diamanti, M. S. Basso, M. Gambarara, B. Papadatou, F. Bracci, C. Noto & M. Castro

Authors
  1. A. Diamanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. S. Basso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Gambarara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Papadatou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Bracci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Noto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Diamanti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diamanti, A., Basso, M.S., Gambarara, M. et al. Positive impact of blocking tumor necrosis factor α on the nutritional status in pediatric Crohn’s disease patients. Int J Colorectal Dis 24, 19–25 (2009). https://doi.org/10.1007/s00384-008-0578-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-008-0578-x

Keywords

Search

Navigation